# US 2021/0330629 A1 · Methods for treating mitochondrial disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330629 A1
- Document ID: US20210330629A1
- Status: Published application
- Kind: A1
- Application number: 16/479,288
- Filed: 2019-02-08
- Published: 2021-10-28
- Earliest claimed: 2018-02-09
- Inventors: Shaoyun LIU
- Web page: https://patentgrep.com/patent/US20210330629A1

## CPC

- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 31/185: Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids (hydroxamic acids A61K31/16; peroxy acids A61K31/327)
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/12: Aerosols; Foams {(A61K9/0043, A61K9/0056, A61K9/006, A61K9/0073 take precedence; spray-films A61K9/7015)}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/205: {Polysaccharides, e.g. alginate, gums; Cyclodextrin}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/2063: {Proteins, e.g. gelatin}
- A61K 9/282: {Organic compounds, e.g. fats}
- A61K 9/485: {Inorganic compounds}
- A61K 9/4858: {Organic compounds}
- A61K 9/4875: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/4858)}
- A61K 31/26: Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61K 47/6951: {using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 13/08: of the prostate
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/06: Antipsoriatics
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/06: Anabolic agents (androgens A61P5/26)
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides pharmaceutical and nutraceutical compositions and methods for the treatment of mitochondrial disorders. The pharmaceutical or nutraceutical compositions include a stabilized sulforaphene, such as sulforaphene-cyclodextrin complex, that increases the efficacy, biological activity and stability of isolated sulforaphene. The present disclosure also includes the use of stabilized sulforaphene as an effective therapeutic agent for the treatment of mitochondrial disorders, such as mitochondrial myopathy.

## Claims

### Claim 1

A method for treating a mitochondrial disorder comprising:
administering an effective amount of a stable sulforaphene composition to a subject, wherein the subject has a mitochondrial disorder, said stable sulforaphene composition comprising isolated sulforaphene and a stabilizing agent, and wherein said administration effectively treats said mitochondrial disorder.

### Claim 2 (depends on 1)

The method of claim 1, wherein said mitochondrial disorder a mitochondrial myopathy.

### Claim 3 (depends on 2)

The method of claim 2, wherein said mitochondrial myopathy is selected from the group consisting of chronic fatigue syndrome, essential tremor, psoriasis, skin aging, polycystic ovary syndrome, mitochondrial diabetes, thyroid disease, prostatic hyperplasia, and multiple sclerosis.

### Claim 4 (depends on 3)

The method of claim 3, wherein said mitochondrial myopathy is chronic fatigue syndrome, essential tremor, polycystic ovary syndrome, or psoriasis.

### Claim 5 (depends on 4)

The method of claim 4, wherein mitochondrial myopathy is chronic fatigue syndrome.

### Claim 6 (depends on 1)

The method of claim 1, wherein the stable sulforaphene composition consists essentially of a sulforaphene/cyclodextrin complex.

### Claim 7 (depends on 6)

The method of claim 6, wherein the sulforaphene/cyclodextrin complex is a complex of a sulforaphene and a hydroxypropyl-beta-cyclodextrin.

### Claim 8 (depends on 6)

The method of claim 6, wherein the cyclodextrin is beta cyclodextrin or a hydroxyalkyl derivative thereof.

### Claim 9 (depends on 1)

The method of claim 1, wherein the stable sulforaphene composition is administered as a pharmaceutical formulation or nutraceutical composition.

### Claim 10 (depends on 9)

The method of claim 9, wherein said pharmaceutical composition or nutraceutical composition is administered orally, by injection or topically.

### Claim 11 (depends on 10)

The method of claim 10, wherein said pharmaceutical composition or nutraceutical composition is administrated orally.

### Claim 12 (depends on 9)

The method of claim 9, wherein the pharmaceutical composition or nutraceutical composition is a powder, pill or liquid formulation.

### Claim 13 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 14 (depends on 1)

The method of claim 1, wherein said stable sulforaphene composition is administered to said subject at least once a day.

### Claim 15 (depends on 14)

The method of claim 14, wherein the said stable sulforaphene composition is administered to said subject twice a day for at least two weeks.

### Claim 16

A method for increasing ATP production in a cell comprising:
administering a stable sulforaphene composition to a cell, wherein said stable sulforaphene composition comprises isolated sulforaphene and a stabilizing agent, and wherein said administration increases ATP production by the cell when compared to a cell that is not administered a stable sulforaphene composition.

### Claim 17 (depends on 16)

The method of claim 16, wherein the stable sulforaphene composition consists essentially of a sulforaphene/cyclodextrin complex.

### Claim 18 (depends on 17)

The method of claim 17, wherein the sulforaphene/cyclodextrin complex is a complex of a sulforaphene and a hydroxypropyl-beta-cyclodextrin.

### Claim 19 (depends on 17)

The method of claim 17, wherein the cyclodextrin is beta cyclodextrin or a hydroxyalkyl derivative thereof.

### Claim 20 (depends on 16)

The method of claim 16, wherein the stable sulforaphene composition is administered in an amount selected from the group consisting of 100 μM and 17.5 μg/μL.
